WOONSOCKET, R.I., Feb. 23, 2011 /PRNewswire/ — Xenogenics
Corporation (“Xenogenics”), a majority owned subsidiary of
MultiCell Technologies, Inc. (OTC Bulletin Board MCET), is pleased
to announce it has retained the Emmes Group to assist with the
development and execution of its capital formation strategy to help
finance expanded human clinical trials of its Ideal
BioStent™.
In animal testing and initial human use, the Ideal
BioStent™ demonstrated equivalence in safety, short-term
efficacy, and structural integrity when compared with today’s
leading bare metal stents and drug-eluting metal stents.
Unlike other bioabsorbable stent technologies, the Ideal
BioStent™ showed no stent recoil, both acute and at six month
follow up, remaining well apposed to the vessel wall. The
Ideal BioStent™ is designed to be fully absorbed at 12 months
leaving no metal artifact behind, thereby allowing the vessel to
heal and return to its natural state.
The Ideal BioStent™
- Game changing platform addressing next generation requirements
of multi-billion dollar interventional cardiology market.
- Only platform based on patented bioabsorbable polymer
incorporating anti-inflammatory, anti-thrombotic, and
anti-neoplastic drugs.
- Positive human clinical experience – demonstrated
comparable radial strength with no stent recoil.
- Strong, seminal IP position covering key aspects of technology,
including drug incorporation directly into polymer chain.
- Broad technology platform including coronary and peripheral
stents.
The multi-billion dollar interventional cardiology and
intravascular stent market remains extremely lucrative, and one of
the most at
‘/>”/>
